Side-by-side · Research reference

SNAP-8vsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED8/46 cited

BPhase 2HUMAN-REVIEWED8/46 cited

SNAP-8

Synthetic Octapeptide · Cosmetic Topical

TopicalRoute

8-AAPeptide length

SNAREPrimary target

Topical · Facial application · Twice daily

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter

SNAP-8

TB-500

Primary target

SNARE complex (SNAP-25 competitive binding site)

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Pathway

Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Downstream effect

Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Feedback intact?

N/A — topical cosmetic, no systemic endocrine axis

Endogenous protein at baseline; supplementation amplifies

Origin

Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Antibody development

—

02Dosage Protocols

Parameter

SNAP-8

TB-500

Typical concentration

2–10% in cosmetic formulationsLupin 2024 Raikou 2017

Commercial products typically use 5–10%.

—

Application frequency

Twice daily (morning and evening)Lupin 2024

—

Treatment duration

20–60 days for visible effectRaikou 2017

Skin microtopography improvements measured at 20-day intervals.

—

Formulation type

Oil-in-water emulsion, serum, cream

—

Application site

Facial skin — glabellar lines, crow's feet, forehead

—

Evidence basis

RCT, in vitro skin penetration studies

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Onset of effect

Visible reduction in wrinkle depth by day 20–28Raikou 2017

—

Standard dose

—

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

Frequency

—

2× per week (loading); then 1× per week (maintenance)

Lower / starter dose

—

1 mg per injection

Duration

—

4–8 weeks loading; longer maintenance for chronic injury

Reconstitution

—

Bacteriostatic water, 1–2 mL per 5 mg vial

Timing

—

Evening or pre-rest preferred (anecdotal)

Half-life

—

~2 hours (estimated; tissue uptake longer)

03Metabolic / Fat Loss Evidence

04Side Effects & Safety

Parameter

SNAP-8

TB-500

Cytotoxicity

Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)

Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.

—

Skin irritation

Minimal; well-tolerated in clinical use

—

Peptide oxidation

Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021

Formulation stability issue, not a direct adverse effect.

—

Systemic absorption

Negligible; peptide remains in stratum corneum and epidermisKraeling 2015

—

Hypersensitivity

Rare; no widespread allergic reactions reported

—

Injection site reaction

—

Mild erythema, transient pain

GI symptoms

—

Rare nausea (anecdotal)

Cancer risk

—

Theoretical via angiogenesis pathway

Lethargy / fatigue

—

Reported anecdotally during loading phase

Antibody formation

—

No data (no long-term human trials)

Pregnancy / OB

—

Avoid

Long-term safety

—

Unknown beyond Phase 2

Absolute Contraindications

SNAP-8

·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Relative Contraindications

SNAP-8

·Active skin infections or open wounds at application site
·Neuromuscular disorders (theoretical concern, no documented cases)

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter

SNAP-8

TB-500

1. Cleansing

Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

2. Application

Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

3. Frequency

Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.

Evening or pre-sleep is most common anecdotal timing.

4. Layering

Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Storage

Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.

27–31G, 4–8 mm insulin syringe.

6. Duration

Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.

—

06Stack Synergy

SNAP-8

— no documented stacks

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair